Literature DB >> 18078751

Design and synthesis of substituted 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamides, novel HIV-1 integrase inhibitors.

H Marie Langford1, Peter D Williams, Carl F Homnick, Joseph P Vacca, Peter J Felock, Kara A Stillmock, Marc V Witmer, Daria J Hazuda, Lori J Gabryelski, William A Schleif.   

Abstract

A series of 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamides was synthesized and tested for their inhibition of HIV-1 integrase catalytic activity and HIV-1 replication in cells. Structure-activity studies around lead compound 5 indicated that a coplanar relationship of metal-binding heteroatoms provides optimal binding to the integrase active site. Identification of potency-enhancing substituents and adjustments in lipophilicity provided 17b which inhibits integrase-catalyzed strand transfer with an IC(50) value of 74 nM and inhibits HIV-1 replication in cell culture in the presence of 50% normal human serum with an IC(95) value of 63 nM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18078751     DOI: 10.1016/j.bmcl.2007.11.049

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

Review 1.  Authentic HIV-1 integrase inhibitors.

Authors:  Chenzhong Liao; Christophe Marchand; Terrence R Burke; Yves Pommier; Marc C Nicklaus
Journal:  Future Med Chem       Date:  2010-07       Impact factor: 3.808

2.  A dynamic model of HIV integrase inhibition and drug resistance.

Authors:  Alex L Perryman; Stefano Forli; Garrett M Morris; Catherine Burt; Yuhui Cheng; Michael J Palmer; Kevin Whitby; J Andrew McCammon; Chris Phillips; Arthur J Olson
Journal:  J Mol Biol       Date:  2010-01-22       Impact factor: 5.469

3.  A new synthetic approach for pyrazolo[1,5-a]pyrazine-4(5H)-one derivatives and their antiproliferative effects on lung adenocarcinoma cell line.

Authors:  Meltem Tan Uygun; Karina Amudi; İrem Doğan Turaçlı; Nurettin Menges
Journal:  Mol Divers       Date:  2021-01-02       Impact factor: 2.943

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.